Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-7',8'-dihydro-6'h-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one
2. Cosela
3. Spiro(cyclohexane-1,9'(6'h)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-
1. 1374743-00-6
2. G1t28
3. Cosela
4. Trilaciclib [usan]
5. U6072do9xg
6. 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'h-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
7. Spiro(cyclohexane-1,9'(6'h)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-
8. 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'h-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one
9. G1t28(trilaciclib)
10. G1t28 Di-hcl
11. Trilaciclib [inn]
12. Trilaciclib (usan/inn)
13. Unii-u6072do9xg
14. Trilaciclib [who-dd]
15. Gtpl9626
16. Chembl3894860
17. Schembl10082028
18. Bdbm253928
19. Dtxsid601337125
20. Bcp25013
21. Ex-a4297
22. Nsc816987
23. Db15442
24. Nsc-816987
25. Sb19783
26. Ac-36547
27. Us9464092, T
28. Hy-101467
29. Cs-0021431
30. A17084
31. D11130
32. 2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-7',8'-dihydro-6'h-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one
33. 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'hspiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one
34. 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one
35. 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
Molecular Weight | 446.5 g/mol |
---|---|
Molecular Formula | C24H30N8O |
XLogP3 | 2.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 446.25425761 g/mol |
Monoisotopic Mass | 446.25425761 g/mol |
Topological Polar Surface Area | 91.2 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 707 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer.
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer. It has a short duration of action of approximately 16 hours, and a narrow therapeutic index. Patients should be counselled regarding the risk of injection site reactions, hypersensitivity, and interstitial lung disease.
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AF - Detoxifying agents for antineoplastic treatment
V03AF12 - Trilaciclib
Absorption
Cmax and AUC of trilaciclib increase proportionally with dose.
Route of Elimination
79.1% of a radiolabelled dose is recovered in the feces, 7% as the unchanged parent compound. 14% of a radiolabelled dose is recovered in the urine, 2% as the unchanged parent compound.
Volume of Distribution
The volume of distribution of trilaciclib at steady state is 1130 L.
Clearance
The clearance of trilaciclib is 158 L/h.
Data regarding the metabolism of trilaciclib are not readily available, however it is expected to be extensively metabolised.
The mean terminal half life of trilaciblib is approximately 14 h.
Trilaciclib is inhibits cyclin-dependant kinase 4 (CDK4) at a concentration of 1 nmol/L and cyclin-dependent kinase 5 (CDK5) at 4 nmol/L. Inhibition of CDK2, CDK5, and CDK7 is over 1000-fold less at these concentrations and inhibition of CDK9 is 50-fold less. CDK4 and CDK5 are expressed in hematopoietic stem cells and progenitor cells. They are capable of phosphorylating and inactivating the retinoblastoma protien; a tumor suppressor. When trilaciclib is given to patients with retinoblastoma protein-null small cell lung cancer, it does not interfere with the intended chemotherapy induced cytotoxicity of cancer cells. Inhibition of CDK4 and CDK5 leads to a reversible pause in the cell cycle in the G1 phase for approximately 16 hours. The temporary cell cycle arrest prevents chemotherapy induced DNA damage in healthy cells, reducing the activity of caspases 3 and 7, which reduces apoptosis of healthy cells. Other studies have shown inhibitors of CDK4 and CDK6 enhance T-cell activation, upregulating major histocompatibility complex (MHC) class I and II, and stabilize programmed death-ligand 1 (PD-L1). Together these activities increase T-cell activity, increase antigen presentation, and sensitize cells to immune checkpoint inhibitors.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
A Trilaciclib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trilaciclib, including repackagers and relabelers. The FDA regulates Trilaciclib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trilaciclib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Trilaciclib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Trilaciclib supplier is an individual or a company that provides Trilaciclib active pharmaceutical ingredient (API) or Trilaciclib finished formulations upon request. The Trilaciclib suppliers may include Trilaciclib API manufacturers, exporters, distributors and traders.
click here to find a list of Trilaciclib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Trilaciclib DMF (Drug Master File) is a document detailing the whole manufacturing process of Trilaciclib active pharmaceutical ingredient (API) in detail. Different forms of Trilaciclib DMFs exist exist since differing nations have different regulations, such as Trilaciclib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Trilaciclib DMF submitted to regulatory agencies in the US is known as a USDMF. Trilaciclib USDMF includes data on Trilaciclib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trilaciclib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Trilaciclib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trilaciclib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Trilaciclib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Trilaciclib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Trilaciclib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trilaciclib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Trilaciclib suppliers with NDC on PharmaCompass.
Trilaciclib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trilaciclib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trilaciclib GMP manufacturer or Trilaciclib GMP API supplier for your needs.
A Trilaciclib CoA (Certificate of Analysis) is a formal document that attests to Trilaciclib's compliance with Trilaciclib specifications and serves as a tool for batch-level quality control.
Trilaciclib CoA mostly includes findings from lab analyses of a specific batch. For each Trilaciclib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trilaciclib may be tested according to a variety of international standards, such as European Pharmacopoeia (Trilaciclib EP), Trilaciclib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trilaciclib USP).
LOOKING FOR A SUPPLIER?